Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25360337 | 0.85 | SIGMAR1 (0.48) | USP2SMN1; SMN2AVPR1AGPR119ESR2 | |
| SCHEMBL30623219 | 0.83 | OPRL1 (0.41) | OPRL1RORCAVPR1AGPR119 | |
| SCHEMBL26059137 | 0.83 | OPRL1 (0.41) | OPRL1RORCAVPR1AGPR119 | |
| SCHEMBL26062015 | 0.83 | OPRL1 (0.41) | OPRL1RORCAVPR1AGPR119 | |
| SCHEMBL31387359 | 0.83 | OPRL1 (0.41) | OPRL1RORCAVPR1AGPR119 | |
| SCHEMBL18579748 | 0.82 | USP2 (0.40) | USP2SMN1; SMN2AVPR1AGPR119 | |
| SCHEMBL21710554 | 0.82 | USP2 (0.40) | USP2SMN1; SMN2AVPR1AGPR119 | |
| SCHEMBL20488362 | 0.82 | USP2 (0.40) | USP2SMN1; SMN2AVPR1AGPR119ESR2 | |
| SCHEMBL23223306 | 0.82 | USP2 (0.40) | USP2SMN1; SMN2AVPR1AGPR119 | |
| SCHEMBL18590703 | 0.82 | USP2 (0.40) | USP2SMN1; SMN2AVPR1AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119343353-A | 2-Methyl-4 ',5' -dihydrospiro [ piperidine-4, 7' -thieno [2,3-c ] pyran ] derivatives as APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | ELI LILLY AND COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3589638-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3589638-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY | 2020-02-13 | — | — | US | disclosed |
| EP-3347360-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018160550-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY (US) | 2018-09-07 | — | — | WO | disclosed |
| US-9598431-B1 | Compounds useful for inhibiting ROR-gamma-t | ELI LILLY AND COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170066781-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2017-03-09 | — | — | US | disclosed |
| EP-2501703-B1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8232289-B2 | Spiropiperidine compounds as ORL-1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232289-B2 | Spiropiperidine compounds as ORL-1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232289-B2 | Spiropiperidine compounds as ORL-1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011060217-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060217-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011060035-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011060035-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066781-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | RORC, RORB, RORA | OPRL1 2223/4885RORC 1/4885USP2 2526/4885 |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | RORB, RORC, RORA | OPRL1 1290/4885RORC 2/4885USP2 3449/4885 |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | RORC, RORB, RORA | OPRL1 2178/4885RORC 1/4885USP2 3407/4885 |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | OXER1, OGFRL1, ORMDL3 | OPRL1 4/4885RORC 932/4885USP2 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.